2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

Clinical features of COVID-19 patients in Abdul Wahab Sjahranie Hospital, Samarinda, Indonesia Swandari Paramita*1,2, Ronny Isnuwardana², Marwan Marwan^{2,3}, Donny Irfandi Alfian³, David Hariadi Masihoer³ ¹Center of Excellence for Tropical Studies, Mulawarman University, Samarinda, Indonesia ²Faculty of Medicine, Mulawarman University, Samarinda, Indonesia ³Abdul Wahab Sjahranie Hospital, Samarinda, Indonesia *Corresponding Author: s.paramita@fk.unmul.ac.id Abstract Introduction Coronavirus Disease (COVID-19) is caused by SARS-CoV-2 infection. Indonesia officially established the first COVID-19 confirmation case in early March 2020. East Kalimantan has been determined as a candidate for the new capital of Indonesia since 2019. This makes Abdul Wahab Sjahranie Hospital Samarinda as the largest hospital there has been designated as the main referral hospital for COVID-19 patients in East Kalimantan. We report the epidemiological, clinical, laboratory, and radiological characteristics of these patients. Methods All patients with laboratory-confirmed COVID-19 by RT-PCR were admitted to Abdul Wahab Sjahranie Hospital in Samarinda. We retrospectively collected and analyzed data on patients with standardized data collection from medical records. Results By May 8, 2020, 18 admitted hospital patients had been identified as having laboratoryconfirmed COVID-19. Most of the infected patients were men (16 [88.9%] patients); less than half had underlying diseases (7 [38.9%] patients). Common symptoms at the onset of illness were cough (16 [88.9%] patients), sore throat (8 [44.4%] patients), and fever (8 [44.4%] patients). Laboratory findings of some patients on admission showed anemia. Levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were increased in 10

32 (55.6%) of 18 patients. On admission, abnormalities in chest x-ray images were detected in 6

(33.3%) patients who had pneumonia. The mean duration from the first hospital admission

34 to discharge was 33.1 ± 9.2 days.

Discussion

33

35

41

46

47

- 36 The majority of COVID-19 patients are male. COVID-19 comorbidities were found in several
- 37 patients. The main clinical symptoms of COVID-19 in this study were cough, sore throat, and
- 38 fever. The abnormal laboratory finding in COVID-19 patients is anemia, an increase in AST and
- 39 ALT levels, and chest x-ray images of pneumonia. All patients are in mild condition. The
- 40 average length of hospital admission patients to discharge is more than 30 days.

Conclusion

- 42 Although all patients are in mild condition, the inability of a local laboratory to check for
- 43 positive confirmation of COVID-19 makes the admission period of the patient in the hospital
- 44 very long. The availability of RT-PCR tests at Abdul Wahab Sjahranie Hospital Samarinda will
- 45 greatly assist the further management of COVID-19 patients.

Introduction

- 48 Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
- 49 coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2, an RNA virus from the Coronaviridae
- family, can be transmitted to humans and animals (1). Although most coronavirus infections
- 51 in humans are mild, there have been two epidemics of beta coronavirus throughout history,
- 52 namely severe acute respiratory syndrome (SARS) (2) and Middle East respiratory syndrome
- 53 (MERS) (3), which have caused more than 10,000 cases in the last two decades, with a
- mortality rate of 10% for SARS (4) and 37% for MERS (5).
- 55 In December 2019, a series of pneumonia cases with unknown causes emerged in Wuhan,
- 56 China, in which the clinical findings are similar to viral pneumonia. (6). The sequencing
- 57 analysis from respiratory tract samples indicated a new coronavirus, which was then named
- 58 SARS-CoV-2 (7). Until the end of May 2020, there are more than 5 million positive confirmed
- 59 cases of COVID-19 worldwide, with the USA, Brazil, and Russia as countries for the most cases
- 60 in the world (8).
- 61 Indonesia officially established its first COVID-19 confirmation case on March 2, 2020 from
- 62 the capital of Jakarta (9). Meanwhile the first case of COVID-19 from East Kalimantan, a

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

province of Indonesia in Borneo island, was reported on March 18, 2020, which was a patient from Abdul Wahab Sjahranie Hospital in Samarinda city (10). East Kalimantan province has been determined as a candidate for the new capital of the Republic of Indonesia by 2019 (11). Therefore, the flow of people in and out of East Kalimantan has been increasing rapidly, especially in Samarinda as the capital of the province. This movement of people plays an important role in the spread of COVID-19 in Samarinda. Abdul Wahab Sjahranie Hospital, the largest hospital in Samarinda, has been designated as the main referral hospital for COVID-19 patients in Samarinda (12). Currently, there is no previous study has been done which describe the COVID-19 cases from East Kalimantan. Therefore, the study aims to describe the epidemiological, clinical, laboratory, and radiological characteristics of COVID-19 patients who are admitted at Abdul Wahab Sjahranie Hospital Samarinda. Methods **Patients** The subjects in this study were all patients admitted at Abdul Wahab Sjahranie Hospital with laboratory confirmation of positive COVID-19 results from nasopharyngeal swabs from March to May 2020. This study was approved by the Ethical Health Research Commission of Abdul Wahab Sjahranie Hospital (No. 070/Diklit/1328/IV/2020). **Procedures** Nasopharyngeal swab samples were taken when the patient was admitted to the hospital, then the samples were sent to the Center for Health Laboratory in Surabaya, Indonesia as an official examination laboratory for COVID-19 by the Ministry of Health of the Republic of Indonesia. Nasopharyngeal swabs samples were then examined to confirm COVID-19 using RT-PCR according to guidelines from the Ministry of Health of the Republic of Indonesia. A positive COVID-19 patient with clinical improvement can be discharged from the hospital if the followup results of RT-PCR examination from nasopharyngeal swab samples of two days in a row show negative results. Data collection

This study collected data on the hospital medical records of all patients with positive

confirmation of COVID-19. Data was taken from patients admitted to the hospital from March

95 14, 2020 to May 2, 2020. Epidemiological, clinical, laboratory and radiological data of patients

were reviewed with standardized data collection forms from hospital medical records. Two

researchers independently reviewed data collection to double-check the data obtained.

Statistical analysis

- Continuous variables were expressed as mean ± SD; categorical variables were expressed as
- 100 frequency and percentage. Statistical analyses were done using Microsoft Excel.

Results

96

97

98

99

101

- 103 By May 8, 2020, 18 admitted hospital patients had been identified as having laboratory-
- 104 confirmed COVID-19. Five (27.8%) of the COVID-19 patients were aged 30-39 years, and 4
- 105 (22.2%) were aged 60-69 years. The mean age of the patients was 44 ± 15.5 years. Most of
- the infected patients were men (16 [88.9%]); less than half had underlying diseases (7
- 107 [38.9%]), including hypertension (4 [22.2%]), cardiovascular disease (2 [11.1%]), and diabetes
- 108 (1 [5.56%]).
- The most common symptoms at onset of illness were cough (16 [88.9%] of 18 patients), sore
- throat (8 [44.4%]), and fever (8 [44.4%]); less common symptoms were runny nose (7 [38.9%],
- myalgia or fatigue (6 [33.3%]), dyspnea (5 [27.8%]), headache (4 [22.2%]), and nausea (4
- 112 [22.2%]). The mean duration from first hospital admission to COVID-19 laboratory
- 113 confirmation was 10 ± 3.6 days, and to hospital discharge was 33.1 ± 9.2 days.
- The blood counts of patients on admission showed leukocytosis (white blood cell count more
- than 10.8x10⁹/L; 2[11.1%] of 18 patients), lymphopenia (lymphocyte count < 19%; 3 [16.7%]
- patients), neutrophilia (neutrophil count > 74%; 3 [16.7%] patients), and monocytosis
- 117 (monocytes count > 9%; 3 [16.7%] patients). Laboratory findings of patients on admission also
- showed low hemoglobin level (hemoglobin < 14 g/L; 6 [33.3%] patients), low erythrocytes
- 119 count (red blood cell count < 4.7 x10⁶ per L; 5 [27.8%] patients), and high platelet large cell
- ratio (P-LCR > 25 g/L; 4 [22.2%] patients). All patients had high platelet distribution width
- 121 (PDW > 13 g/L) on admission. Levels of aspartate aminotransferase (AST) and alanine
- aminotransferase (ALT) were increased in 10 (55.6%) of 18 patients. All patients had normal
- serum levels of procalcitonin on admission (0.26 \pm 0.1 u/L). On admission, abnormalities in
- radiographic images were detected in 6 (33.3%) patients which had pneumonia.

As of May 23, 2020, all patients have been discharged. Patients with clinical improvement can be discharged from the hospital if the results of RT-PCR examination two days in a row show negative results.

Table 1. Demographics and baseline characteristics of COVID-19 patients

Characteristics	Mean ± SD or N (%)
Age, years	44 ± 15.5
20-29 years	3 (16.7)
30-39 years	5 (27.8)
40-49 years	3 (16.7)
50-59 years	3 (16.7)
60-69 years	4 (22.2)
Sex	
Men	16 (88.9)
Women	2 (11.1)
Sources of transmission	
Imported cases from Gowa, South Sulawesi	12 (66.7)
Imported cases from other places	6 (33.3)
Local transmission within Samarinda	0 (0)
History of comorbidity	7 (38.9)
Hypertension	4 (22.2)
Cardiovascular disease	2 (11.1)
Diabetes mellitus	1 (5.6)
BMI, kg/m ²	23.7 ± 2.8
BMI > 25 kg/m ²	5 (27.8)

Table 2. Signs and symptoms characteristics of COVID-19 patients

Signs and symptoms	Mean ± SD or N (%)
--------------------	--------------------

Systolic pressure, mmHg	128.8 ± 17.7
Diastolic pressure, mmHg	83.5 ± 11.6
Blood pressure >= 140/90 mmHg	7 (38.9)
Respiratory rate, per min	20.7 ± 1.6
Temperature, °C	36.7 ± 0.6
Temperature >= 37 °C	8 (44.4)
Cough	16 (88.9)
Sore throat	8 (44.4)
Fever	8 (44.4)
Runny nose	7 (38.9)
Myalgia or fatigue	6 (33.3)
Dyspnea	5 (27.8)
Headache	4 (22.2)
Nausea	4 (22.2)
Days from the first admission to COVID-19 confirmation	10 ± 3.6
Days from the first admission to hospital discharge	33.1 ± 9.2

Table 3. Laboratory findings of COVID-19 patients on hospital admission

Laboratory findings	Mean ± SD or N (%)
Red blood cell count, x10 ⁶ per L	5.1 ± 0.6
Red blood cell count < 4.7 x10 ⁶ per L	5 (27.8)
Hemoglobin, g/L	14.7 ± 1.9
Hemoglobin < 14 g/L	6 (33.3)
Hematocrit, g/L	43.8 ± 4.7
Hematocrit < 37 g/L	2 (11.1)
Mean Corpuscular Volume (MCV), g/L	86.3 ± 5.4
MCV <81 g/L	2 (11.1)
Mean Corpuscular Hemoglobin (MCH), g/L	29.1 ± 2.4
MCH <27 g/L	2 (11.1)

MCH >31 g/L	2 (11.1)
Mean Corpuscular Hemoglobin Concentration (MCHC), g/L	33.6 ± 1.1
MCHC <33 g/L	1 (5.6)
Red Cell Distribution Width – Standard Deviation (RDW-SD), g/L	40.4 ± 2.6
Red Cell Distribution Width – Corpuscular Volume (RDW-CV), g/L	13.3 ± 1.4
RDW-CV > 14.5 g/L	1 (5.6)
Platelet count, x10 ³ per L	280.6 ± 85.9
Platelet count < 150 x10 ³ per L	1 (5.6)
Platelet Distribution Width (PDW), g/L	16.1 ± 0.3
PDW > 13 g/L	18 (100)
Mean Platelet Volume (MPV), g/L	9.3 ± 0.8
Platelet Large Cell Ratio (P-LCR), g/L	22.8 ± 6.1
P-LCR < 15 g/L	1 (5.6)
P-LCR > 25 g/L	4 (22.2)
Procalcitonin (PCT), g/L	0.26 ± 0.1
Aspartate aminotransferase (AST), U/L	43.4 ± 23.6
AST > 40 U/L	10 (55.6)
Alanine aminotransferase (ALT), U/L	56.6 ± 53.6
ALT > 41 U/L	10 (55.6)

Table 4. White blood cell laboratory findings of COVID-19 patients on hospital admission

Laboratory findings	Mean ± SD or N (%)
White blood cell count, x10 ³ per L	7.8 ± 2.3
White blood cell count > 10.8 x10 ³ per L	2 (11.1)
Neutrophil count, x10 ⁹ per L	4.8 ± 2.2
Neutrophil count > 7 x10 ⁹ per L	2 (11.1)
Neutrophil count, %	59.9 ± 13.4
Neutrophil count > 74%	3 (16.7)
Neutrophil count < 40%	1 (5.6)

Lymphocytes count, x10 ⁹ per L	2.3 ± 1.1
Lymphocytes count, %	30.6 ± 12.3
Lymphocytes count > 48%	1 (5.6)
Lymphocytes count < 19%	3 (16.7)
Monocytes count, x10 ⁹ per L	0.5 ± 0.1
Monocytes count, %	6.9 ± 1.9
Monocytes count > 9%	3 (16.7)
Eosinophils count, x10 ⁹ per L	0.2 ± 0.2
Eosinophil count > 0,8 x10 ⁹ per L	1 (5.6)
Eosinophils count, %	2.7 ± 2.4
Eosinophil count >7%	1 (5.6)

Table 5. Radiographs findings of COVID-19 patients on hospital admission

Radiographs findings	
Abnormalities in chest x-ray	
Ground glass opacity appearance	4 (22.2)
Unilateral	2 (11.1)
Bilateral	2 (11.1)
Consolidation appearance	2 (11.1)
Diagnoses on hospital admission based on chest x-ray	
Pneumonia	6 (27.8)

Discussion

This study reports of 18 patients with positive COVID-19 confirmations admitted at Abdul Wahab Sjahranie Hospital Samarinda, Indonesia. As of May 24, 2020, there have been 276 positive COVID-19 positive confirmation cases in East Kalimantan (13). There are 22,271 positive confirmed cases of COVID-19, with 5,402 people recovering and 1,372 patients have died in Indonesia on May 24, 2020 (14).

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

The majority of COVID-19 patients in Abdul Wahab Sjahranie Hospital are male. This is consistent with a meta-analysis study which showed that men took the largest percentage in the distribution of COVID-19 according to gender (15). Other studies have shown that SARS-CoV and MERS-CoV also infect more men than women (16). The low vulnerability of women to viral infections is thought to be caused by the protective effect of the X chromosome (17) and the effects of sex hormones such as estrogen and progesterone, which play an important role in the immune system (18). COVID-19 comorbidities were found in several patients in this study, such as hypertension, cardiovascular disease, and diabetes. This is consistent with a systematic review study and meta-analysis that shows that the major comorbidities are hypertension and diabetes, followed by cardiovascular disease. (19). This chronic disease is related to the pathogenesis of COVID-19. Chronic disease has a standard picture similar to infectious diseases, especially in the immune system (20). Metabolic disorders can reduce immune function by inhibiting the work of macrophages and lymphocyte function, thus making a person more susceptible to complications from a disease (21). The main clinical symptoms of COVID-19 in this study were cough, sore throat, and fever. This is consistent with a meta-analysis study showing that the main clinical symptoms of COVID-19 patients are fever and cough (15). COVID-19 patients generally present with similar symptoms, such as fever, cough, and sore throat. Most patients with SARS-CoV-2 infection will appear with mild flu-like symptoms (22). Several COVID-19 patients had anemia, which is a low level of hemoglobin and red blood cell count. This can be caused by the initial condition of the patient at the hospital who already has anemia. Iron deficiency is a form of anemia that is common in patients admitted to hospitals in Indonesia (23). A study found that iron deficiency anemia can affect the immune response and cytokine activity in the body (24). This can increase the vulnerability to be infected with COVID-19. Another abnormal laboratory finding in COVID-19 patients here is an increase in AST and ALT levels which are parameters of liver function. This is similar to other studies that the laboratory examination results of COVID-19 patients showed that 76.3% had impaired liver function (25). Impaired liver function related to COVID-19 can be caused directly by a viral infection or other conditions such as the use of drugs that are hepatotoxic or due to systemic inflammatory responses, hypoxic conditions due to respiratory distress, and multiorgan

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

dysfunction (26). If impaired liver function occurs, hepatoprotective drugs are recommended to be given to these patients (27). Abnormal chest x-ray images of pneumonia were only found in 6 patients in this study. This is similar to other studies that found that consolidation and ground-glass opacity are chest xray findings in patients with positive confirmation of COVID-19 (28). The description of bilateral pneumonia with ground-glass opacity appearance in this study is consistent with the results of a systematic review and meta-analysis of COVID-19 (29). All patients are in mild condition and none of the patients admitted to intensive care. This is consistent with studies that estimate the number of asymptomatic patients for COVID-19 around less than half (30). As of May 24, 2020, only 3 fatal cases of laboratory-confirmed COVID-19 were reported in East Kalimantan (13). Most of the COVID-19 patients admitted to hospitals in East Kalimantan are in mild condition. The average length of time a patient starts in the hospital until the laboratory positive COVID-19 is confirmed is more than 10 days. This is due to the nasopharyngeal swab sample from Abdul Wahab Sjahranie Hospital being sent to the Center for Health Laboratory of the Ministry of Health in Surabaya, Indonesia. This laboratory serves the examination of reference specimens from the provinces of East, Central, South, and North Kalimantan (12). As of May 24, 2020, there were 276 positive cases in East Kalimantan, 308 in Central Kalimantan, 599 in South Kalimantan, and 164 North Kalimantan (31). The large number of samples that must be examined up to 4 provinces makes the slow progress of laboratory examination. Patients must wait a long time for laboratory confirmation results of COVID-19. The average length of hospital admission patients to discharge is more than 30 days. This is because COVID-19 patients with clinical improvement can only be discharged from the hospital if the results of RT-PCR examination two days in a row show negative results (32). Based on the explanation above, the large number of samples that had to be examined from 4 provinces in Kalimantan by the Center for Health Laboratory of the Ministry of Health made patients wait longer for negative COVID-19 confirmation results. Our study has several limitations. First, with a limited number of cases, this is a series of small patient cases. Data collection for larger studies will help to better determine the clinical picture and risk factors for this disease. Second, there is a potential exposure bias and no children were reported as patients in this study. More efforts must be made to answer these questions in further research.

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

Conclusion All COVID-19 patients in this study were in mild condition with symptoms of fever, cough, and sore throat. Most patients were male and had comorbidities which can increase the risk of COVID-19. Anemic conditions and increased AST/ALT levels in some patients need attention during patient care in the hospital. Although all patients are in mild condition, the inability of a local laboratory in East Kalimantan to check for positive confirmation of COVID-19 extended the admission period of the patient in the hospital unnecessarily. Therefore, the availability of RT-PCR tests at Abdul Wahab Sjahranie Hospital Samarinda will greatly assist the further management of COVID-19 patients. **REFERENCES** 1. Richman D, Whitley R, Hayden F. Clinical Virology. 4th ed. Washington: ASM Press; 2016. Drosten C, Günther S, Preiser W, Van Der Werf S, Brodt HR, Becker S, et al. 2. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967-76. 3. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814-20. WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 4. to 31 July 2003. World Health Organization. 2003. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). World Health 5. Organization. 2019. 6. WHO. Novel Coronavirus - China. World Health Organization. 2020. 7. Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus—The species and its viruses, a statement of the Coronavirus Study Group. BioRxiv. 2020; Worldometer. COVID-19 Coronavirus Pandemic. Worldometer. 2020. 8. Gorbiano MI. BREAKING: Jokowi announces Indonesia's first two confirmed COVID-19 9. cases. The Jakarta Post. 2020 Mar 2; 10. Kumparan. Kasus Positif Corona Pertama di Kaltim, Pasien Pernah Ikut Seminar di Bogor. Kumparan. 2020 Mar 18;

- 251 11. Maulia E. Jokowi announces Indonesia's new capital in East Kalimantan. Nikkei Asian
- 252 Review. 2019 Aug 26;
- 253 12. Ministry of Health Republic of Indonesia. COVID-19. Infeksi Emerging. 2020.
- 254 13. Dinas Kesehatan Provinsi Kalimantan Timur. Dinas Kesehatan Provinsi Kalimantan
- Timur [Internet]. COVID-19. 2020 [cited 2020 May 24]. Available from:
- 256 https://covid19.kaltimprov.go.id
- 257 14. Kementerian Kesehatan RI. Situasi Terkini Perkembangan Coronavirus Disease
- 258 (COVID-19). Kementerian Kesehatan RI. 2020.
- 259 15. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients'
- clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol.
- 261 2020;92(6):577–83.
- 262 16. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory
- 263 syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J
- 264 Infect Dis. 2016;49:129–33.
- 265 17. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-based
- 266 differences in susceptibility to severe acute respiratory syndrome coronavirus
- 267 infection. J Immunol. 2017;198(10):4046–53.
- 268 18. Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. Clin Rev
- 269 Allergy Immunol. 2017;1–14.
- 270 19. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the
- 271 novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-
- 272 analysis. Int J Infect Dis. 2020;
- 273 20. Odegaard JI, Chawla A. Connecting type 1 and type 2 diabetes through innate
- immunity. Cold Spring Harb Perspect Med. 2012;2(3):p.a007724.
- 275 21. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two
- 276 epidemics. Lancet Infect Dis. 2009;9(12):737–46.
- 277 22. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
- with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
- 279 23. Syam AF, Sobur CS, Abdullah M, Makmun D. Nutritional Status of Hospitalized
- Nonsurgery Patients at A Nationwide Referral Hospital in Indonesia. J Int Dent Med
- 281 Res. 2018;11(2):732–9.
- 282 24. Ekiz C, Agaoglu L, Karakas Z, Gurel N, Yalcin I. The effect of iron deficiency anemia on

- the function of the immune system. Hematol J. 2005;5(7):579.
- 284 25. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. Characteristics of liver tests in COVID-19
- patients. J Hepatol. 2020;
- 286 26. Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, et al. COVID-19 and liver
- 287 dysfunction: current insights and emergent therapeutic strategies. J Clin Transl
- 288 Hepatol. 2020;8(1):18.
- 289 27. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges.
- 290 Lancet Gastroenterol Hepatol. 2020;5(5):428–30.
- 291 28. Wong HYF, Lam HYS, Fong AHT, Leung ST, Chin TWY, Lo CSY, et al. Frequency and
- 292 distribution of chest radiographic findings in COVID-19 positive patients. Radiology.
- 293 2020;p.201160.
- 294 29. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R,
- 295 Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features
- of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis.
- 297 2020;p.101623.
- 298 30. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S, Hayashi K, et al. Estimation of
- the asymptomatic ratio of novel coronavirus infections (COVID-19). medRxiv. 2020;
- 300 31. Gugus Tugas Percepatan Penanganan COVID-19. Situasi virus COVID-19 di Indonesia.
- 301 Gugus Tugas Percepatan Penanganan COVID-19. 2020.
- 302 32. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit. Pedoman Pencegahan
- dan Pengendalian Coronavirus Disease (COVID-19). Jakarta, Indonesia: Kementerian
- 304 Kesehatan RI; 2020.